| Nov 18 |
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
|
| Nov 5 |
NLS and Kadimastem stocks soar following merger agreement
|
| Nov 5 |
NLS Pharmaceutics, Kadimastem enter definitive merger agreement
|
| Nov 4 |
NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem
|
| Nov 4 |
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
|
| Oct 28 |
NLS Pharmaceutics regains compliance with Nasdaq
|
| Oct 28 |
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
|
| Oct 21 |
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence
|
| Oct 15 |
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
|
| Sep 25 |
NLS Pharmaceutics to conduct reverse share split
|
